BSH 2023 | Session highlights: IDH inhibitors, salvage regimens, and other novel developments in AML

Steven Knapper, MRCP, FRCPath, DM, Cardiff University, Cardiff, UK, gives an overview of the topics presented in a session held at BSH which focused on novel developments in acute myeloid leukemia (AML). Prof. Knapper first discusses recent updates from the Phase III AGILE study (NCT03173248), highlighting that the addition of ivosidenib to azacitidine could improve clinical outcomes in patients with AML ineligible for intensive chemotherapy. Following this, Prof. Knapper discusses retrospective data looking at the outcomes of patients with relapsed/refractory (R/R) AML receiving venetoclax in combination with azacitidine or low-dose cytarabine, and concludes by commenting on the importance of further assessing these regimens in clinical trials and developing a unified funding strategy to improve access to therapy. This interview took place at the 63rd Annual Scientific Meeting of the British Society for Haematology (BSH) 2023, held in Birmingham, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.